About: MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1(+) tumor immunity in mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1(+) tumor immunity in mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1(+) tumor immunity in mice
Creator	Yang, Ming Wang, Liying Fang, Mingli Wan, Min Yu, Yongli Wu, Xiuli Song, Dandan Wei, Hongfei Yan, Youyou Zhang, Xiaoling Zhao, Tiesuo
Source	Elsevier; Medline; PMC
abstract	MF59 is an oil-in-water emulsion adjuvant approved for influenza vaccines for human use in Europe. Due to its Th2 inducing properties, MF59 is seldom tested for cancer vaccines. In this study, MF59 formulated with a C-type CpG oligodeoxynucleotide (YW002) was tested for its Th1 adjuvant activity to induce immune responses to HSP65-MUC1, a recombinant fusion protein incorporating a mycobacterial heat shock protein (HSP65) and mucin 1, cell surface associated (MUC1) derived peptide. Combination of YW002 with MF59 (MF59-YW002) could confer a potent Th1 biasing property to the adjuvant, which enhanced the immunogenicity of HSP65-MUC1 to induce significantly higher levels of specific IgG2c, increased IFN-γ mRNA expression in splenocytes and the generation of antigen-specific cytotoxic T lymphocytes in mice. When prophylactically applied, MF59-YW002 adjuvant containing HSP65-MUC1 inhibited the growth of MUC1(+) B16 melanoma and prolonged the survival of tumor-bearing mice. In contrast, adjuvant containing MF59 with HSP65-MUC1 in the absence of YW002, promoted the growth of MUC1(+) B16 melanoma in mice. These results suggest that MF59 plus CpG oligodeoxynucleotide might be developed as an efficient adjuvant for tumor vaccines against melanoma, and possibly other tumors.
has issue date	2012-05-14(xsd:dateTime)
bibo:doi	10.1016/j.intimp.2012.05.003
bibo:pmid	22595192
has license	no-cc
sha1sum (hex)	9c5443d8bf13edb87f6b39e2e0d58b7b1bbaf67c
schema:url	https://doi.org/10.1016/j.intimp.2012.05.003
resource representing a document's title	MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1(+) tumor immunity in mice
has PubMed Central identifier	PMC7106219
has PubMed identifier	22595192
schema:publication	Int Immunopharmacol
resource representing a document's body	covid:9c5443d8bf13edb87f6b39e2e0d58b7b1bbaf67c#body_text
is schema:about of	named entity 'IFN-γ' named entity 'MF59' named entity 'tested' named entity 'MUC1' named entity 'immunogenicity' named entity 'adjuvant' named entity 'oil-in-water emulsion' named entity 'tumor immunity' named entity 'OIL' named entity 'GROWTH' named entity 'SPLENOCYTES' named entity 'TH1' named entity 'PROTEIN ' named entity 'EFFICIENT' named entity 'CONTAINING' named entity 'RECOMBINANT' named entity 'IMMUNOGENICITY' named entity 'SELDOM' named entity 'DERIVED' named entity 'FUSION PROTEIN' named entity 'CPG OLIGODEOXYNUCLEOTIDE' named entity '2C CELL' named entity 'ENHANCED' covid:arg/9c5443d8bf13edb87f6b39e2e0d58b7b1bbaf67c named entity 'EUROPE' named entity 'ACTIVITY' named entity 'MICE' named entity 'INDUCING' named entity 'APPROVED' named entity 'INHIBITED' named entity 'THESE' named entity 'MRNA EXPRESSION' named entity 'ADJUVANT' named entity 'RECOMBINANT' named entity 'MF59' named entity 'TUMOR IMMUNITY' named entity 'HSP65' named entity 'CPG ODN' named entity 'ABSENCE OF' named entity 'T LYMPHOCYTES' named entity 'PROLONGED' named entity 'MYCOBACTERIAL' named entity 'COMBINATION' named entity 'TUMOR VACCINES' named entity 'ADJUVANT' named entity 'DUE TO' named entity 'APPLIED' named entity 'PROPERTIES' named entity 'INCREASED' named entity 'GENERATION' named entity 'MUC1' named entity 'ITS' named entity 'CELL SURFACE' named entity 'INDUCE' named entity 'HEAT SHOCK PROTEIN' named entity 'TUMOR' named entity 'MUC1' named entity 'PEPTIDE' named entity 'HSP65' named entity 'BEARING' named entity 'RESULTS' named entity 'POSSIBLY' named entity 'LEVELS' named entity 'CANCER VACCINES' named entity 'IMMUNE RESPONSES' named entity 'TESTED FOR' named entity 'WATER' named entity 'CYTOTOXIC' named entity 'MELANOMA' named entity 'MIGHT BE' named entity 'SURVIVAL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software